Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Lirafugratinib |
| Trade Name | Lyrfigtu |
| Synonyms | RLY4008|RLY 4008|RLY-4008 |
| Drug Descriptions |
Lyrfigtu (lirafugratinib) is a selective, irreversible FGFR2 inhibitor that blocks FGFR2 signaling, potentially lead to tumor growth inhibition (PMID: 38300868). Lyrfigtu (lirafugratinib) is FDA-approved for use in patients with previously treated advanced or metastatic cholangiocarcinoma harboring FGFR2 fusion or rearrangement (FDA.gov). |
| DrugClasses | FGFR2 Inhibitor 24 |
| CAS Registry Number | 2549174-42-5 |
| NCIT ID | C174208 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Lirafugratinib | Lirafugratinib | 17 | 2 |